UCB's Keppra Follow-On Briviact Gains FDA Nod For Epileptic Seizures
This article was originally published in The Pink Sheet Daily
Executive Summary
A next-generation version of levetiracetam, brivaracetam could help UCB recapture some revenue it's losing to generic competition for the mature epilepsy drug.
You may also be interested in...
UCB Predicts Briviact Sales Of €450m by 2026; Plans New Partnerships
UCB says its early to mid-stage pipeline contains 10 promising breakthrough molecules, some of which it aims to partner with other pharma players as part of its open innovation strategy.
UCB Exercises Tozadenant Option But Asks Biotie To Move It To Phase III
Biotie Therapies gets $20 million as UCB exercises its option on the investigational Parkinson's disease therapy tozadenant and asks the Finnish biotech to continue its clinical development of the product into Phase III.
Epilepsy NMEs: A View Of The Playing Field
The late-stage pipeline for novel epilepsy treatments stars a handful of specialty and foreign firms, but the early-stage lineup makes room for new firms and the products of academic research. Venture philanthropy is a big factor, but the poor funding climate for CNS firms may limit play.